Indaptus Therapeutics Inc (INDP) - Total Assets
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) holds total assets worth $6.84 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See INDP book value for net asset value and shareholders' equity analysis.
Indaptus Therapeutics Inc - Total Assets Trend (2008–2024)
This chart illustrates how Indaptus Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Indaptus Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Indaptus Therapeutics Inc's total assets of $6.84 Million consist of 90.2% current assets and 9.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Indaptus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Indaptus Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indaptus Therapeutics Inc's current assets represent 90.2% of total assets in 2024, an increase from 41.0% in 2008.
- Cash Position: Cash and equivalents constituted 78.9% of total assets in 2024, up from 30.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Indaptus Therapeutics Inc Competitors by Total Assets
Key competitors of Indaptus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Indaptus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 3.42 | 0.86 |
| Quick Ratio | 2.88 | 3.42 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.20 Million | $5.40 Million | $-283.50K |
Indaptus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Indaptus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | -50.8% |
| Total Assets | $7.34 Million |
| Market Capitalization | $3.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Indaptus Therapeutics Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Indaptus Therapeutics Inc's assets decreased by 50.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Indaptus Therapeutics Inc (2008–2024)
The table below shows the annual total assets of Indaptus Therapeutics Inc from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.34 Million | -50.83% |
| 2023-12-31 | $14.92 Million | -46.82% |
| 2022-12-31 | $28.06 Million | -30.84% |
| 2021-12-31 | $40.58 Million | +2182.41% |
| 2020-12-31 | $1.78 Million | -91.65% |
| 2019-12-31 | $21.28 Million | -65.40% |
| 2018-12-31 | $61.51 Million | -4.71% |
| 2017-12-31 | $64.55 Million | +161.11% |
| 2016-12-31 | $24.72 Million | -33.68% |
| 2015-12-31 | $37.28 Million | +198.35% |
| 2014-12-31 | $12.49 Million | -8.67% |
| 2013-12-31 | $13.68 Million | +76.09% |
| 2012-12-31 | $7.77 Million | -14.25% |
| 2011-12-31 | $9.06 Million | -27.76% |
| 2010-12-31 | $12.54 Million | +280.87% |
| 2009-12-31 | $3.29 Million | +52.51% |
| 2008-12-31 | $2.16 Million | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency… Read more